TMS vs. ECT: Comparing Brain Stimulation Therapies for Severe Depression

When antidepressants and therapy haven't provided adequate relief from depression, brain stimulation therapies offer a fundamentally different approach — one that works directly on the neural circuits involved in mood regulation rather than through systemic medication.

The two most established brain stimulation therapies for depression are transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). Both are effective, both are evidence-based, and both are appropriate for different patients in different circumstances.

Understanding the differences between them — in mechanism, efficacy, side effects, and patient experience — is essential for making an informed treatment decision.

At Roth Family Medicine & Mental Health in Pocatello, Idaho, we offer TMS therapy and can help you understand whether TMS, ECT, or another approach is right for your situation.

Transcranial magnetic stimulation (TMS) uses a magnetic coil placed against the scalp to deliver focused magnetic pulses to specific regions of the brain — primarily the left dorsolateral prefrontal cortex (DLPFC), which is underactive in depression.

These magnetic pulses induce small electrical currents in the targeted brain tissue, stimulating neural activity and promoting neuroplasticity. Over a course of treatment, TMS gradually normalizes activity in the depression-related neural circuits.

Key facts about TMS:

• Non-invasive — no surgery, no anesthesia, no seizure
• Outpatient procedure — patients drive themselves to and from appointments
• Standard course: 36 sessions over 6–9 weeks (newer protocols are faster)
• FDA-cleared for major depressive disorder (2008), OCD (2018), anxious depression (2021), and smoking cessation (2020)
• Patient is awake and alert throughout; can resume normal activities immediately after

Electroconvulsive therapy (ECT) delivers a brief electrical current through electrodes placed on the scalp to intentionally induce a generalized seizure under general anesthesia. Despite its dramatic history and persistent stigma, modern ECT is a safe, highly effective medical procedure.

Key facts about ECT:

• Requires general anesthesia and muscle relaxants
• Administered in a hospital or outpatient surgical setting
• Standard course: 6–12 sessions over 2–4 weeks (3 times per week)
• Maintenance ECT (monthly or as needed) often required to prevent relapse
• Patient is unconscious during the procedure; recovery room time required
• Requires someone to drive the patient home after each session

TMS works through neuroplasticity — gradually reshaping neural circuits through repeated stimulation. The primary effects include:

• Increased activity in the underactive left DLPFC
• Normalization of connectivity between the DLPFC and limbic system (emotional brain)
• Promotion of long-term potentiation (LTP) — strengthening of neural connections
• Modest increases in BDNF and other neurotrophic factors
• Gradual normalization of default mode network activity (rumination circuits)

TMS effects are cumulative and build over weeks of treatment.

ECT's mechanism is less fully understood but involves more dramatic and immediate neurobiological effects:

• Massive release of neurotransmitters (serotonin, dopamine, norepinephrine, GABA) during the seizure
• Rapid upregulation of BDNF and neuroplasticity
• Normalization of HPA axis function
• Anti-inflammatory effects
• Possible effects on neurogenesis

ECT produces rapid, dramatic effects — often within 1–2 weeks — that are not fully explained by any single mechanism.

• Response rate (≥50% symptom reduction): approximately 50–60% in treatment-resistant depression
• Remission rate (near-complete symptom resolution): approximately 30–35%
• Effects are durable — studies show maintained response at 12 months in most responders
• Efficacy is higher in patients who have failed fewer prior antidepressants
• Newer protocols (theta burst stimulation, deep TMS) may improve response rates

• Response rate: approximately 70–80% in treatment-resistant depression — among the highest of any psychiatric treatment
• Remission rate: approximately 50–60%
• Particularly effective for severe depression with psychotic features, catatonia, and acute suicidality
• Rapid onset — significant improvement often within 1–2 weeks
• High relapse rate without maintenance treatment (50–80% relapse within 6 months without continuation therapy)

Bottom line on efficacy: ECT is more effective than TMS, particularly for severe, treatment-resistant cases. However, TMS is effective for a substantial proportion of patients and has a much more favorable side effect profile.

TMS has a remarkably benign side effect profile:

Common (usually mild and transient):

• Scalp discomfort or mild headache during or after treatment (resolves within hours)
• Scalp muscle twitching during treatment
• Temporary hearing sensitivity (ear protection is provided)

Rare:

• Seizure (risk is approximately 1 in 10,000 sessions — lower than the background risk in the general population)
• Syncope (fainting)

No cognitive side effects — TMS does not cause memory problems, confusion, or cognitive impairment. Patients can drive, work, and function normally throughout treatment.

ECT's side effects are more significant and are the primary reason many patients and providers prefer TMS when appropriate:

Common:

• Memory impairment — the most significant concern with ECT
  • Anterograde amnesia: difficulty forming new memories during and shortly after the treatment course
  • Retrograde amnesia: loss of memories from the weeks to months surrounding treatment; some patients experience more extensive retrograde memory loss
  • Memory typically improves after treatment ends, but some patients report persistent gaps
• Confusion and disorientation immediately after each session (typically resolves within hours)
• Headache after sessions
• Muscle aches from the muscle relaxant
• Nausea

Serious but rare:

• Cardiovascular complications (from anesthesia and the seizure)
• Prolonged seizure
• Anesthesia-related risks

Cognitive effects are the primary limitation of ECT and the reason many patients are reluctant to pursue it despite its high efficacy.

• Arrive at the clinic, sit in a reclining chair
• Technician positions the magnetic coil against your scalp
• Treatment begins — you feel a tapping or knocking sensation on your scalp, hear a clicking sound
• 19–37 minutes later (depending on protocol), treatment is complete
• You get up, drive yourself to work or home, and go about your day
• Repeat 5 days per week for 6–9 weeks

Most patients describe TMS as mildly uncomfortable at first, becoming routine within the first week. Many read, listen to music, or simply relax during sessions.

• Arrive at the hospital or outpatient surgical center
• IV placed, anesthesia administered
• Procedure takes approximately 5–10 minutes
• Wake up in recovery room, typically confused and disoriented for 30–60 minutes
• Headache and fatigue common for the rest of the day
• Cannot drive; need someone to take you home
• Repeat 3 times per week for 2–4 weeks

ECT is more disruptive to daily life and work, and the post-procedure confusion and memory effects can be distressing.

TMS is appropriate for:

• Moderate-to-severe depression that hasn't responded to 1–4 antidepressants
• Patients who want to avoid anesthesia and cognitive side effects
• Patients who need to maintain work and daily functioning during treatment
• Patients with medical conditions that increase anesthesia risk
• Patients who are not acutely suicidal or in immediate danger
• Patients who prefer a non-invasive, outpatient approach
• OCD, anxious depression, and smoking cessation (FDA-cleared indications)

ECT is appropriate for:

• Severe, life-threatening depression with acute suicidality or inability to care for oneself
• Depression with psychotic features (delusions, hallucinations)
• Catatonia
• Patients who have failed multiple treatments including TMS and ketamine
• Patients who need the fastest possible response (ECT works faster than TMS)
• Patients who have previously responded well to ECT
• Pregnancy (ECT is considered safer than most psychiatric medications during pregnancy)

For patients with treatment-resistant depression, TMS, ECT, and ketamine therapy represent three distinct and complementary approaches:

Many patients benefit from combinations — for example, ketamine for rapid relief while TMS builds its cumulative effect, or TMS after ECT to maintain remission with fewer cognitive side effects.

We offer TMS therapy at our Pocatello clinic for patients with treatment-resistant depression, OCD, and anxious depression. Our TMS program includes:

• Comprehensive evaluation to determine candidacy
• Individualized treatment planning
• Close monitoring throughout the treatment course
• Coordination with your existing mental health providers
• Integration with other treatments (ketamine, medication management, therapy) as appropriate

If you're considering brain stimulation therapy and want to understand your options, we'd be glad to discuss whether TMS is right for you.

Call us at (208) 904-4705 or book a consultation online. We're accepting new patients in Pocatello, Chubbuck, Bannock County, and throughout Southeast Idaho.

• TMS and ECT are both effective brain stimulation therapies for treatment-resistant depression
• ECT has higher efficacy (70–80% response) but significant cognitive side effects, particularly memory impairment
• TMS has lower but still substantial efficacy (50–60% response) with essentially no cognitive side effects
• TMS is outpatient, requires no anesthesia, and allows patients to maintain normal daily functioning
• ECT is preferred for life-threatening depression, psychotic features, catatonia, and when the fastest possible response is needed
• Ketamine, TMS, and ECT can be used in combination for comprehensive treatment of severe depression
• Roth Family Medicine & Mental Health offers TMS therapy in Pocatello, Idaho

Kyle Roth, FNP-BC, APRN, MSN, MHA is a board-certified family nurse practitioner specializing in TMS therapy, ketamine therapy, and treatment-resistant depression at Roth Family Medicine & Mental Health in Pocatello, Idaho.

This article is for informational purposes only and does not constitute medical advice.